Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity

Nov 03 2011

• By PharmAsia News

Related Content

Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market

Mar 23 2011

With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics

Aug 05 2011

Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 2 of 2)

Aug 11 2011

GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)

Nov 01 2011

Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center

Nov 11 2008

Pricing Under The Spotlight As Novo Files Next-Generation Insulins

Oct 10 2011

Lilly Shifts Gears In China With New Shanghai-based R&D Center

Nov 03 2010

Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus

Apr 26 2009

Biopharma Industry Slated As China Pillar Industry, But Key Domestic Support Missing

Jun 19 2009

More from Archive

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window